Serum chromogranin-A in hepatocellular carcinoma: Diagnostic utility and limits

Table 1 Clinical-demographic data and serum CGA values.

	HCC	LC	CH	CRF	CHF	IBD	Controls
Number of patients	54	132	45	36	27	45	75
Male/female	39/15	93/39	30/15	18/18	12/15	30/15	51/24
Age (yr)	69±11	59±12	52±13	71±17	72±15	45±6	48±15
CgA (ng/mL)	769±1 046	249±369	87±94 1	390±1 401	577±539	146±287	48±18
α-FP (ng/mL)	79±160	10±13
Child–Pugh class
A	12	36
B	15	57
C	27	39

Abbreviations: HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic hepatitis; IBD, inflammatory bowel disease; CRF, chronic renal failure; CHF, chronic heart failure.

Table 2 P values relative to comparison of serum CgA levels between paired groups (NPC test).

Groups	HCC	LC	CH	IBD	CRF	CHF
L C	0.004
CH	0.000	0.167
IBD	0.004	0.171	0.817
CRF	0.100	0.768	0.000	0
CHF	0.333	0.025	0.000	0.004	0.057
Controls	0.000	0.000	0.022	0.000	0.000	0

Abbreviations: HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic hepatitis; IBD, inflammatory bowel disease; CRF, chronic renal failure; CHF, chronic heart failure.